DepoCyte

RSS

Withdrawn

This medicine's authorisation has been withdrawn

cytarabine
MedicineHumanWithdrawn

Latvian is available via eTranslation, the European Commission's machine translation service.

Translate to Latvian | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 10 July 2018, the European Commission withdrew the marketing authorisation for DepoCyte (cytarabine) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Pacira Ltd, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. 

DepoCyte was granted marketing authorisation in the EU on 11 July 2001 for the intrathecal treatment of lymphomatous meningitis. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2011. 

The European Public Assessment Report (EPAR) for DepoCyte is updated to reflect the fact that the marketing authorisation is no longer valid.

български (BG) (661.62 KB - PDF)

Skatīt

español (ES) (569.14 KB - PDF)

Skatīt

čeština (CS) (632.39 KB - PDF)

Skatīt

dansk (DA) (569.13 KB - PDF)

Skatīt

Deutsch (DE) (714.1 KB - PDF)

Skatīt

eesti (ET) (568.03 KB - PDF)

Skatīt

ελληνικά (EL) (1.25 MB - PDF)

Skatīt

français (FR) (569.55 KB - PDF)

Skatīt

italiano (IT) (572.16 KB - PDF)

Skatīt

latviešu (LV) (637.75 KB - PDF)

Skatīt

lietuvių (LT) (593.61 KB - PDF)

Skatīt

magyar (HU) (627.27 KB - PDF)

Skatīt

Malti (MT) (571.84 KB - PDF)

Skatīt

Nederlands (NL) (568.96 KB - PDF)

Skatīt

polski (PL) (632.99 KB - PDF)

Skatīt

português (PT) (570.42 KB - PDF)

Skatīt

română (RO) (592.76 KB - PDF)

Skatīt

slovenčina (SK) (630.99 KB - PDF)

Skatīt

slovenščina (SL) (626.68 KB - PDF)

Skatīt

suomi (FI) (568.87 KB - PDF)

Skatīt

svenska (SV) (568.38 KB - PDF)

Skatīt

Product information

български (BG) (1.36 MB - PDF)

Skatīt

español (ES) (798.17 KB - PDF)

Skatīt

čeština (CS) (1.18 MB - PDF)

Skatīt

dansk (DA) (840.85 KB - PDF)

Skatīt

Deutsch (DE) (1.1 MB - PDF)

Skatīt

eesti (ET) (770.12 KB - PDF)

Skatīt

ελληνικά (EL) (2.4 MB - PDF)

Skatīt

français (FR) (786.49 KB - PDF)

Skatīt

hrvatski (HR) (322.7 KB - PDF)

Skatīt

italiano (IT) (780.81 KB - PDF)

Skatīt

latviešu (LV) (1.15 MB - PDF)

Skatīt

lietuvių (LT) (800.85 KB - PDF)

Skatīt

magyar (HU) (1.14 MB - PDF)

Skatīt

Malti (MT) (1.13 MB - PDF)

Skatīt

Nederlands (NL) (776.99 KB - PDF)

Skatīt

polski (PL) (1.13 MB - PDF)

Skatīt

português (PT) (778.53 KB - PDF)

Skatīt

română (RO) (897.66 KB - PDF)

Skatīt

slovenčina (SK) (1.11 MB - PDF)

Skatīt

suomi (FI) (771.39 KB - PDF)

Skatīt

svenska (SV) (765.06 KB - PDF)

Skatīt

Íslenska (IS) (279.42 KB - PDF)

Skatīt

norsk (NO) (284.34 KB - PDF)

Skatīt
Latest procedure affecting product information:N/0059
26/06/2017
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (538.83 KB - PDF)

Skatīt

español (ES) (512.35 KB - PDF)

Skatīt

čeština (CS) (531.7 KB - PDF)

Skatīt

dansk (DA) (506.59 KB - PDF)

Skatīt

eesti (ET) (496.5 KB - PDF)

Skatīt

ελληνικά (EL) (520.27 KB - PDF)

Skatīt

français (FR) (505.96 KB - PDF)

Skatīt

italiano (IT) (502.84 KB - PDF)

Skatīt

latviešu (LV) (531.14 KB - PDF)

Skatīt

lietuvių (LT) (517.85 KB - PDF)

Skatīt

magyar (HU) (522.39 KB - PDF)

Skatīt

Malti (MT) (533.64 KB - PDF)

Skatīt

Nederlands (NL) (505.52 KB - PDF)

Skatīt

polski (PL) (531.52 KB - PDF)

Skatīt

português (PT) (512.51 KB - PDF)

Skatīt

română (RO) (518.92 KB - PDF)

Skatīt

slovenčina (SK) (530.76 KB - PDF)

Skatīt

slovenščina (SL) (520.2 KB - PDF)

Skatīt

suomi (FI) (502.61 KB - PDF)

Skatīt

svenska (SV) (513.13 KB - PDF)

Skatīt

Product details

Name of medicine
DepoCyte
Active substance
cytarabine
International non-proprietary name (INN) or common name
cytarabine
Therapeutic area (MeSH)
Meningeal Neoplasms
Anatomical therapeutic chemical (ATC) code
L01BC01

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Intrathecal treatment of lymphomatous meningitis. In the majority of patients such treatment will be part of symptomatic palliation of the disease.

Authorisation details

EMA product number
EMEA/H/C/000317
Marketing authorisation holder
Pacira Limited

3 Glory Park Avenue
Wooburn Green
High Wycombe
Buckinghamshire
HP10 0DF
United Kingdom

Opinion adopted
10/07/2018
Marketing authorisation issued
11/07/2001
Revision
15

Assessment history

This page was last updated on

Share this page